Agilent Technologies, Inc.

NYSE A

Agilent Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending October 31, 2024: USD 6.51 B

Agilent Technologies, Inc. Revenue is USD 6.51 B for the Trailing 12 Months (TTM) ending October 31, 2024, a -4.73% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Agilent Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending October 31, 2023 was USD 6.83 B, a -0.22% change year over year.
  • Agilent Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending October 31, 2022 was USD 6.85 B, a 8.37% change year over year.
  • Agilent Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending October 31, 2021 was USD 6.32 B, a 18.36% change year over year.
  • Agilent Technologies, Inc. Revenue for the Trailing 12 Months (TTM) ending October 31, 2020 was USD 5.34 B, a 3.41% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
NYSE: A

Agilent Technologies, Inc.

CEO Mr. Rodney Gonsalves
IPO Date Nov. 18, 1999
Location United States
Headquarters 5301 Stevens Creek Boulevard
Employees 17,400
Sector Health Care
Industries
Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Similar companies

RVTY

Revvity, Inc.

USD 120.73

-1.61%

GH

Guardant Health, Inc.

USD 37.46

-1.68%

CRL

Charles River Laboratories International, Inc.

USD 178.08

-6.34%

WAT

Waters Corporation

USD 404.93

1.26%

IDXX

IDEXX Laboratories, Inc.

USD 418.63

-0.94%

TMO

Thermo Fisher Scientific Inc.

USD 556.99

0.27%

MTD

Mettler-Toledo International Inc.

USD 1.27 K

0.33%

DHR

Danaher Corporation

USD 237.62

-0.94%

ILMN

Illumina, Inc.

USD 136.48

-5.37%

StockViz Staff

January 15, 2025

Any question? Send us an email